Edwards Lifesciences Corp- 详细介绍、公司背景、业务范围、财务数据以及市场表现

关于 Edwards Lifesciences Corp 公司

Edwards Lifesciences Corporation 是一家全球性结构性心脏创新公司。该公司致力于以患者为中心的结构性心脏病医疗创新，并投资于研发，以改变结构性心脏病患者的护理。其产品分为几类，包括经导管主动脉瓣置换术 (TAVR)、经导管二尖瓣和三尖瓣治疗 (TMTT) 和外科结构性心脏 (外科)。该公司开发了经导管心脏瓣膜置换技术，旨在以微创方式置换主动脉瓣膜。Edwards SAPIEN 系列瓣膜包括 Edwards SAPIEN 3、Edwards SAPIEN 3 Ultra 和 Edwards SAPIEN 3 Ultra RESILIA 系统，这些系统是基于导管的治疗方法，用于治疗严重的症状性主动脉瓣狭窄。其 PASCAL PRECISION 和 Cardioband 经导管瓣膜修复系统已在欧洲上市，用于二尖瓣和三尖瓣修复。

公司简介

公司代码EW

公司名称Edwards Lifesciences Corp

上市日期Mar 27, 2000

成立日期1999

CEOMr. Bernard J. Zovighian

员工数量15800

证券类型Ordinary Share

年结日Mar 27

公司地址One Edwards Way

城市IRVINE

上市交易所NYSE Consolidated

国家United States of America

邮编92614

电话19492502500

网址https://www.edwards.com

公司代码EW

上市日期Mar 27, 2000

成立日期1999

公司高管

名称

名称/职务

职务

持股

持股变动

Mr. Scott B. Ullem

Chief Financial Officer, Corporate Vice President

273.31K

--

Mr. Larry L. Wood

Corporate Vice President, Group President - Transcatheter Aortic Valve Replacement (TAVR) and Surgical Structural Heart

178.00K

-0.19%

Mr. Steven R. (Steve) Loranger

Independent Director

71.32K

--

Mr. Daniel J. Lippis

Corporate Vice President - JAPAC (Japan, Greater China and Asia Pacific)

22.23K

--

Mr. Bernard J. Zovighian

Chief Executive Officer, Director

17.95K

--

Mr. Daveen Chopra

Corporate Vice President - Transcatheter Mitral and Tricuspid Therapies

13.29K

-51.80%

Mr. Paul A. Laviolette

Independent Director

7.72K

-3.16%

Dr. David T. Feinberg, M.D.

Independent Director

2.31K

--

Mr. Nicholas J. (Nick) Valeriani

Independent Chairman of the Board

--

Mr. Kieran T. Gallahue

Independent Director

--

名称

名称/职务

职务

持股

持股变动

Mr. Scott B. Ullem

Chief Financial Officer, Corporate Vice President

273.31K

--

Mr. Larry L. Wood

Corporate Vice President, Group President - Transcatheter Aortic Valve Replacement (TAVR) and Surgical Structural Heart

178.00K

-0.19%

Mr. Steven R. (Steve) Loranger

Independent Director

71.32K

--

Mr. Daniel J. Lippis

Corporate Vice President - JAPAC (Japan, Greater China and Asia Pacific)

22.23K

--

Mr. Bernard J. Zovighian

Chief Executive Officer, Director

17.95K

--

Mr. Daveen Chopra

Corporate Vice President - Transcatheter Mitral and Tricuspid Therapies

13.29K

-51.80%

收入明细

单位: USD更新时间: 4月6日周日

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

FY2018

FY2017

FY2016

FY2015

业务USD

名称

营收

占比

Transcatheter Aortic Valve Replacement

4.11B

75.49%

Surgical Heart Valve Therapy

981.30M

18.04%

Transcatheter Mitral and Tricuspid Therapies

352.10M

6.47%

地区USD

名称

营收

占比

United States

3.21B

58.94%

Europe

1.32B

24.30%

Rest of the world

572.00M

10.52%

Japan

339.80M

6.25%

业务

地区

业务USD

名称

营收

占比

Transcatheter Aortic Valve Replacement

4.11B

75.49%

Surgical Heart Valve Therapy

981.30M

18.04%

Transcatheter Mitral and Tricuspid Therapies

352.10M

6.47%

股东统计

更新时间: 4月16日周三

持股股东

股东类型

持股股东

股东统计

占比

The Vanguard Group, Inc.

11.71%

Wellington Management Company, LLP

5.65%

BlackRock Institutional Trust Company, N.A.

5.40%

State Street Global Advisors (US)

4.39%

Geode Capital Management, L.L.C.

2.32%

Other

70.53%

持股股东

股东统计

占比

The Vanguard Group, Inc.

11.71%

Wellington Management Company, LLP

5.65%

BlackRock Institutional Trust Company, N.A.

5.40%

State Street Global Advisors (US)

4.39%

Geode Capital Management, L.L.C.

2.32%

Other

70.53%

股东类型

股东统计

占比

Investment Advisor/Hedge Fund

44.56%

Investment Advisor

31.06%

Hedge Fund

3.82%

Pension Fund

2.37%

Research Firm

2.13%

Bank and Trust

1.79%

Sovereign Wealth Fund

1.50%

Individual Investor

0.89%

Endowment Fund

0.82%

Other

11.06%

机构持股

更新时间: 1月19日周日

报告期

机构数

持股数

持股占比

持股变动

2025Q1

2552

530.96M

90.30%

-2.24M

2024Q4

2597

531.64M

90.42%

-4.10M

2024Q3

2568

511.38M

84.93%

-20.94M

2024Q2

2559

522.19M

86.68%

-12.58M

2024Q1

2572

518.82M

86.18%

-12.08M

2023Q4

2573

509.93M

84.08%

-27.42M

2023Q3

2530

522.96M

86.03%

-18.75M

2023Q2

2517

523.54M

86.35%

-20.02M

2023Q1

2495

522.98M

86.26%

-32.79M

2022Q4

2485

532.76M

86.16%

-12.94M

股东持股明细

名称

持股数

占比

持股变动

变动比例

公告日期

The Vanguard Group, Inc.

68.87M

11.71%

+6.55M

+10.50%

Dec 31, 2024

Wellington Management Company, LLP

33.21M

5.65%

+1.68M

+5.32%

Dec 31, 2024

BlackRock Institutional Trust Company, N.A.

31.74M

5.4%

-1.09M

-3.33%

Dec 31, 2024

State Street Global Advisors (US)

25.81M

4.39%

-457.01K

-1.74%

Dec 31, 2024

Geode Capital Management, L.L.C.

13.65M

2.32%

+126.19K

+0.93%

Dec 31, 2024

JP Morgan Asset Management

10.76M

1.83%

+6.05M

+128.20%

Dec 31, 2024

Fisher Investments

9.78M

1.66%

+696.97K

+7.68%

Dec 31, 2024

Citadel Advisors LLC

9.42M

1.6%

+7.43M

+372.91%

Dec 31, 2024

Walter Scott & Partners Ltd.

9.41M

1.6%

-720.79K

-7.12%

Dec 31, 2024

Norges Bank Investment Management (NBIM)

8.25M

1.4%

-285.79K

-3.35%

Dec 31, 2024

持股ETF

更新时间: 4月6日周日

机构名称

占比

iShares U.S. Medical Devices ETF

4.32%

Future Fund Long/Short ETF

3.05%

Global X Aging Population ETF

2.15%

Themes US R&D Champions ETF

1.97%

Tema Cardiovascular and Metabolic ETF

1.77%

iShares Health Innovation Active ETF

1.67%

SPDR S&P Health Care Equipment ETF

1.61%

ROBO Global Healthcare Technology & Innovation ETF

1.56%

Invesco S&P 500 Equal Weight Health Care ETF

1.54%

First Trust Indxx Medical Devices ETF

1.41%

iShares U.S. Medical Devices ETF

占比4.32%

Future Fund Long/Short ETF

占比3.05%

Global X Aging Population ETF

占比2.15%

Themes US R&D Champions ETF

占比1.97%

Tema Cardiovascular and Metabolic ETF

占比1.77%

iShares Health Innovation Active ETF

占比1.67%

SPDR S&P Health Care Equipment ETF

占比1.61%

ROBO Global Healthcare Technology & Innovation ETF

占比1.56%

Invesco S&P 500 Equal Weight Health Care ETF

占比1.54%

First Trust Indxx Medical Devices ETF

占比1.41%

分红派息

近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股

公告日期

类型

比率

May 07, 2020

Split

1>3

公告日期

类型

比率

May 07, 2020

Split

1>3

Edwards Lifesciences Corp

76.280USD

Edwards Lifesciences Corp

76.280

概览

公司